Following an extensive global search process conducted by Legacy
MEDSearch, dsm-firmenich is thrilled to announce the appointment of
Paul Spencer as the new President of
the Biomedical business. Spencer will replace former President,
John Witkowski.
EXTON,
Pa., July 15, 2024 /PRNewswire-PRWeb/ -- With
over 30 years of experience in strategy development, people
leadership, innovation enablement, and profitable growth
strategies, Paul is a seasoned healthcare executive across a
diverse range of markets including advanced drug delivery,
implantable medical devices, biomaterials, and excipients.
"I am truly honored and humbled to be the
next President of dsm-firmenich Biomedical." - Paul Spencer
Paul first started his career as a U.S. Army aviation officer,
serving domestically and abroad. After finishing his military
service, he held sales and distributor roles at Biomet, Inc., with
a focus on craniomaxillofacial and neurosurgery solutions.
Following his career at Biomet, Paul's next role was in business
development for biodegradable biomaterials and parenteral drug
delivery.
In 2005 Paul co-founded Brookwood Pharmaceutical and its wholly
owned biomaterial subsidiary, Lakeshore Biomaterials. That business
was sold to Surmodics, where he held numerous leadership roles, and
later to Evonik. At Evonik, Paul was responsible for their drug
delivery and medical device polymer business, culminating in his
most recent executive position as SVP of Drug Products. He also
represented Evonik's Nutrition and Care Division on the North
American Leadership Team upon returning to the US from Germany, where he resided from 2015-2023.
"I'm extremely happy to have found who I think is the best fit
for the President role at dsm-firmenich Biomedical," says Philip
Eykerman, President – Health, Nutrition & Care (HNC). "Paul is
a capable leader who possesses strengths that go beyond his
industry expertise. I have no doubt that our Biomedical business
will continue to thrive under his leadership."
Paul adds, "I am truly honored and humbled to be the next
President of dsm-firmenich Biomedical." Based in Exton, Pennsylvania near Biomedical's Global
Headquarters facility, he looks forward to collaborating across
dsm-firmenich and continuing the company's mission of bringing
progress to life.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich
reinvents, manufactures, and combines vital nutrients, flavors, and
fragrances for the world's growing population to thrive. With our
comprehensive range of solutions, with natural and renewable
ingredients and renowned science and technology capabilities, we
work to create what is essential for life, desirable for consumers,
and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch
company, listed on the Euronext Amsterdam, with operations in
almost 60 countries and revenues of more than €12 billion. With a
diverse, worldwide team of nearly 30,000 employees, we bring
progress to life™ every day, everywhere, for billions of
people.
www.dsm-firmenich.com
About Biomedical
As the world's unrivaled biomaterials expert and committed
partner in driving sustainable innovation in healthcare, Biomedical
is at the forefront of biomaterial science and process innovation.
The company's technologies and support are recognized for their
unmatched quality, reliability, and performance in multiple markets
worldwide. To learn more, visit dsm-firmenich.com/biomedical.
Media Contact
Kathena Siegel, dsm-firmenich, 1 (215) 539-3255,
kathena.siegel@dsm-firmenich.com, dsm-firmenich.com/biomedical
LinkedIn
View original content to download
multimedia:https://www.prweb.com/releases/dsm-firmenich-announces-paul-spencer-as-new-president-of-biomedical-business-302195947.html
SOURCE dsm-firmenich